Compassionate use: Putting drug regulations to the test
When should pharmaceutical companies grant compassionate use of experimental treatments? How readily available should the drugs be? A PBS news segment considers these issues.
When should pharmaceutical companies give gravely ill patients access to experimental treatments? The above news segment offers an good summary of the issues involved in this vexed ethical dilemma.
Compassionate Use Putting drug regulations to the test
Xavier Symons
https://www.bioedge.org/images/2008images/TH_savejosh.jpg
Creative commons
clinical trials
compassionate use
Xavier Symons is a bioethicist and scholar in residence at the Kennedy Institute for Ethics at Georgetown University.
Latest posts by Xavier Symons (see all)
- Can machines be moral? - March 7, 2021
- Can we synthesise Christianity moral theology with secular bioethics? - November 28, 2020
- Euthanasia polling data may fail to capture people’s considered views - August 15, 2020
More Stories
A first in France: a trans mum and a trans dad
Trigger warning: if you are easily confused by gender pronouns, this story from France may cause heart palpitations. February 19...
Nigerian power couple convicted in London over organ trafficking plot
In May last year, a young Nigerian man stumbled into a police station into the English town of Staines, in...
Cease and desist: Dutch sperm donor who has fathered 550 children is being sued
A Dutch woman and a foundation for children of sperm donors are suing a Dutch man for fathering too many...
Should intractable mental illness make you eligible for euthanasia?
Canada is in the middle of a vigorous debate about whether incurable mental illness is grounds for Medical Assistance in...
Belgium to permit multiple gender ID changes
Belgium will permit people to change their gender identity as often as they want. The Minister of Justice, Vincent Van...
Nature’s foray into politics may have backfired
In the 2020 election, a swag of high-profile science journals, including Nature, Science, The Lancet, and the New England Journal...